A 68-Year-Old Man with Diffuse Large B-Cell Lymphoma

home / case-based-peer-perspectives / a-68-year-old-man-with-diffuse-large-b-cell-lymphoma

Ian Flinn, MD, PhD, reviews the case of a 68-year-old man with two relapses of DLBCL, discusses the challenges of R/R DLBCL management and the potential treatment options, and highlights the critical needs of such patients.

Introduction: A 68-Year-Old Man with Diffuse Large B-Cell Lymphoma

EP. 1: Introduction: A 68-Year-Old Man with Diffuse Large B-Cell Lymphoma

Ian Flinn, MD, PhD
August 19th 2022

Ian Flinn, MD, PhD, presents the case of a 68-year-old man with diffuse large B-cell lymphoma (DLBCL) and 2 relapses after complete disease remission.

Watch

Second-Line Treatment Approaches for R/R DLBCL

EP. 2: Second-Line Treatment Approaches for R/R DLBCL

Ian Flinn, MD, PhD
August 19th 2022

An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.

Watch

Available Treatment Options in DLBCL with 2 or More Relapses

EP. 3: Available Treatment Options in DLBCL with 2 or More Relapses

Ian Flinn, MD, PhD
August 19th 2022

Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.

Watch

An Oncologist’s Perspective on Future Treatment Options for the Profiled Patient and Targeted Treatment Approaches in R/R DLBCL

EP. 4: An Oncologist’s Perspective on Future Treatment Options for the Profiled Patient and Targeted Treatment Approaches in R/R DLBCL

Ian Flinn, MD, PhD
August 19th 2022

An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.

Watch

Critical Unmet Needs in DLBCL

EP. 5: Critical Unmet Needs in DLBCL

Ian Flinn, MD, PhD
August 19th 2022

Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.

Watch